TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tango Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
215M of 169M shares
Institutional holders
247
78 new, 22 sold out
Net institutional buying
37M
In Q2 2026
Insider trades, 12 months
0 buys · 24 sales
Net sold $11.87M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 9,905,919 | 6.90% | 13G (passive) | Mar 31, 2026 |
| The Goldman Sachs Group, Inc. | 9,742,403 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Giauque, Nicolas | 9,157,000 | 8.40% | 13G (passive) amendment | Jun 30, 2025 |
| TCG Crossover Fund II, L.P. | 8,536,196 | 6.30% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 8,477,165 | 6.30% | 13G (passive) | Dec 31, 2025 |
| Aaron I. Davis | 8,339,935 | 7.80% | 13D (active) amendment | Oct 10, 2024 |
| Rocco Sgobbo | 7,266,081 | 5.10% | 13G (passive) amendment | Mar 31, 2026 |
| Dunn Hannah E. | 7,182,000 | 6.60% | 13G (passive) | Jun 6, 2025 |
| BCTG Holdings, LLC | 6,988,450 | 6.50% | 13D (active) amendment | Nov 6, 2024 |
| Warren, John R. | 16,270,187 | 9.80% | 13G (passive) amendment | Jun 30, 2026 |
| TCG Crossover GP II, L.P. | 13,521,839 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Short Daniel S. | 13,461,215 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| RTW Investments, LP | 13,300,620 | 9.30% | 13G (passive) | Mar 31, 2026 |
| Adage Capital Management, L.P. | 12,809,485 | 8.98% | 13G (passive) amendment | Mar 31, 2026 |
| TCG Crossover GP II, LLC | 11,597,737 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Linn, Michael G. | 11,257,203 | 7.80% | 13G (passive) amendment | Mar 31, 2026 |
| Gehani, Varun N. | 10,757,000 | 9.70% | 13G (passive) amendment | Sep 30, 2025 |
| Davis Aaron I. | 10,740,385 | 10.00% | 13D (active) amendment | Dec 30, 2024 |
| Oleg Nodelman | 10,630,736 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Chen Yu | 10,147,867 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TNGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 13,900,620 | 8.24% | $434.53M | +600,000 | 3.71% |
| BlackRock, Inc. | 12,438,444 | 7.38% | $388.83M | +3,690,399 | 0.01% |
| FMR LLC | 12,333,339 | 7.31% | $385.54M | +2,427,420 | 0.02% |
| Farallon Capital Management LLC | 12,277,000 | 7.28% | $383.78M | +3,179,589 | 1.77% |
| Boxer Capital Management, LLC | 10,876,219 | 6.45% | $339.99M | – | 25.61% |
| Goldman Sachs Group Inc | 9,980,620 | 5.92% | $311.99M | +4,904,228 | 0.03% |
| TCG Crossover Management, LLC | 9,081,201 | 5.39% | $283.88M | −1,449,870 | 6.82% |
| Trv Gp Iv, LLC | 6,374,574 | 3.78% | $120.18M | – | 47.37% |
| Paradigm Biocapital Advisors LP | 6,357,523 | 3.77% | $198.74M | +2,347,844 | 3.72% |
| Price T Rowe Associates Inc /Md/ | 6,348,827 | 3.77% | $198.47K | +5,459,427 | 0.02% |
| Siren, L.L.C. | 6,179,364 | 3.66% | $193.17M | +522,259 | 3.91% |
| State Street Corp | 5,979,806 | 3.55% | $186.93M | +1,327,912 | 0.01% |
| Vanguard Capital Management LLC | 5,957,348 | 3.53% | $186.23M | +795,917 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 5,600,000 | 3.32% | $175.06M | −7,209,485 | 0.25% |
| Jupiter Topco LLC | 5,056,352 | 3.00% | $157.99M | New | 0.06% |
| Deep Track Capital, LP | 4,200,000 | 2.49% | $131.29M | +1,450,000 | 1.91% |
| Deerfield Management Company, L.P. (Series C) | 4,190,611 | 2.49% | $131.00M | +43,798 | 1.37% |
| Woodline Partners LP | 4,000,567 | 2.37% | $125.06M | −3,999,446 | 0.39% |
| Geode Capital Management, LLC | 3,742,791 | 2.22% | $117.02M | +1,067,014 | 0.01% |
| Perceptive Advisors LLC | 3,377,000 | 2.00% | $105.57M | +2,568,847 | 1.58% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 247 | 215M | 100.0% | 78 / 102 | 55 / 22 | 68M | 31M |
| Q1 2026 | 194 | 180M | 100.0% | 59 / 64 | 56 / 32 | 48M | 33M |
| Q4 2025 | 170 | 173M | 100.0% | 53 / 75 | 27 / 22 | 73M | 40M |
| Q3 2025 | 141 | 140M | 83.0% | 37 / 48 | 35 / 10 | 27M | 14M |
| Q2 2025 | 115 | 127M | 75.6% | 21 / 41 | 31 / 28 | 28M | 8M |
| Q1 2025 | 122 | 107M | 63.6% | 17 / 43 | 38 / 30 | 13M | 6M |
| Q4 2024 | 137 | 106M | 63.1% | 44 / 40 | 28 / 27 | 41M | 36M |
| Q3 2024 | 121 | 102M | 60.2% | 18 / 39 | 36 / 15 | 15M | 8M |
| Q2 2024 | 120 | 99M | 58.5% | 20 / 38 | 34 / 25 | 4M | 4M |
| Q1 2024 | 126 | 99M | 58.6% | 22 / 36 | 40 / 16 | 12M | 7M |
| Q4 2023 | 121 | 94M | 55.7% | 37 / 42 | 21 / 16 | 14M | 9M |
| Q3 2023 | 100 | 89M | 52.7% | 22 / 33 | 26 / 11 | 22M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TNGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,395,732 | 2.61% | $137.41M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,607,345 | 2.14% | $112.77M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,891,041 | 1.71% | $90.37M | 0.84% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,472,200 | 1.47% | $54.34M | 0.06% | May 31, 2026 |
| Select Biotechnology Portfolio | 2,339,362 | 1.39% | $51.42M | 0.98% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,546,027 | 0.92% | $48.33M | 0.33% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,539,756 | 0.91% | $41.85M | 0.12% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,401,293 | 0.83% | $43.80M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,365,330 | 0.81% | $42.68M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,224,795 | 0.73% | $38.29M | 0.25% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,200,590 | 0.71% | $37.53M | 0.38% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 872,500 | 0.52% | $23.71M | 0.48% | Jul 31, 2026 |
| Lord Abbett Developing Growth Fund Inc | 851,196 | 0.50% | $23.14M | 1.04% | Jul 31, 2026 |
| Small Cap Growth Fund | 773,207 | 0.46% | $21.02M | 0.38% | Jul 31, 2026 |
| iShares Biotechnology ETF | 751,469 | 0.45% | $23.49M | 0.26% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Barbara Weber | Director, Executive Chair | 1,629,587 | 0.97% | Feb 4, 2026 |
| Malte Peters | President & CEO, Director | 367,500 | 0.22% | Jan 12, 2026 |
| Jessica Newcomb | Principal Accounting Officer | 66,621 | 0.04% | Sep 24, 2026 |
| Adam Crystal | President, R&D | 142,743 | 0.08% | Sep 3, 2026 |
| Matthew Gall | Chief Financial Officer | 40,000 | 0.02% | May 5, 2026 |
| Daniella Beckman | Chief Financial Officer | 184,297 | 0.11% | Feb 4, 2026 |
| Douglas Barry | General Counsel | 66,014 | 0.04% | Feb 6, 2025 |
| Robert Azelby | Director | 5,740 | 0.00% | Jun 23, 2026 |
| Mace Rothenberg | Director | 41,500 | 0.02% | Jun 8, 2026 |
| Sung Lee | Director | 22,870 | 0.01% | Jun 8, 2026 |
| John B. Ketchum | Director | 24,937 | 0.01% | Jun 8, 2026 |
| Lesley Ann Calhoun | Director | 16,500 | 0.01% | Jun 8, 2026 |
| Alexis Borisy | Director | 17,500 | 0.01% | Jun 9, 2025 |
| Third Rock Ventures IV, L.P. | 10% owner | 17,001,475 | 10.08% | Oct 27, 2025 |
| Trv Gp Iv, Llc | 10% owner | 13,386,574 | 7.94% | Oct 27, 2025 |
| Third Rock Ventures GP IV, L.P. | 10% owner | 15,456,881 | 9.17% | Oct 27, 2025 |
| EcoR1 Capital, LLC | 10% owner | 10,630,736 | 6.30% | Nov 8, 2024 |
| Aaron I. Davis | – | 8,203,642 | 4.87% | Nov 7, 2024 |
| Boxer Capital Management, LLC | – | 10,301,284 | 6.11% | Nov 7, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jessica Newcomb Principal Accounting Officer | Sep 22, 2026 | Sale(10b5-1 plan) | −700 | $22.80 | $15.96K | 66,621 |
| Jessica Newcomb Principal Accounting Officer | Sep 22, 2026 | Sale(10b5-1 plan) | −5,100 | $23.97 | $122.25K | 61,521 |
| Jessica Newcomb Principal Accounting Officer | Sep 22, 2026 | Sale(10b5-1 plan) | −2,400 | $25.17 | $60.41K | 59,121 |
| Adam Crystal President, R&D | Sep 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Adam Crystal President, R&D | Sep 1, 2026 | Sale(10b5-1 plan) | −27,000 | $22.37 | $603.99K | 115,743 |
| Adam Crystal President, R&D | Aug 3, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Adam Crystal President, R&D | Aug 3, 2026 | Sale(10b5-1 plan) | −5,267 | $26.79 | $141.10K | 137,476 |
| Adam Crystal President, R&D | Aug 3, 2026 | Sale(10b5-1 plan) | −21,733 | $27.35 | $594.40K | 115,743 |
| Adam Crystal President, R&D | Jul 1, 2026 | Sale(10b5-1 plan) | −19,629 | $29.34 | $575.91K | 123,114 |
| Adam Crystal President, R&D | Jul 1, 2026 | Sale(10b5-1 plan) | −7,371 | $30.25 | $222.97K | 115,743 |
| Adam Crystal President, R&D | Jul 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Robert Azelby Director | Jun 19, 2026 | Award | +5,740 | – | – | 5,740 |
| Mace Rothenberg Director | Jun 5, 2026 | Award | +4,000 | – | – | 41,500 |
| Sung Lee Director | Jun 5, 2026 | Award | +570 | – | – | 22,870 |
| John B. Ketchum Director | Jun 5, 2026 | Award | +4,000 | – | – | 24,937 |
| Lesley Ann Calhoun Director | Jun 5, 2026 | Award | +4,000 | – | – | 16,500 |
| Adam Crystal President, R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −6,140 | $22.25 | $136.62K | 136,603 |
| Adam Crystal President, R&D | Jun 1, 2026 | Sale(10b5-1 plan) | −20,860 | $23.06 | $481.03K | 115,743 |
| Adam Crystal President, R&D | Jun 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Matthew Gall Chief Financial Officer | May 1, 2026 | Award | +40,000 | – | – | 40,000 |
| Adam Crystal President, R&D | May 1, 2026 | Sale(10b5-1 plan) | −1,100 | $22.00 | $24.20K | 115,743 |
| Adam Crystal President, R&D | May 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 142,743 |
| Adam Crystal President, R&D | May 1, 2026 | Sale(10b5-1 plan) | −25,900 | $21.19 | $548.82K | 116,843 |
| Sung Lee Director | Apr 29, 2026 | Award | +12,300 | – | – | 22,300 |
| Adam Crystal President, R&D | Apr 15, 2026 | Sale(10b5-1 plan) | −38,460 | $25.00 | $961.50K | 112,622 |
| Adam Crystal President, R&D | Apr 15, 2026 | Option exercise | +38,460 | $5.20 | $199.99K | 151,082 |
| Adam Crystal President, R&D | Apr 1, 2026 | Option exercise | +27,000 | $5.20 | $140.40K | 139,622 |
| Adam Crystal President, R&D | Apr 1, 2026 | Sale(10b5-1 plan) | −27,000 | $21.20 | $572.40K | 112,622 |
| Adam Crystal President, R&D | Mar 25, 2026 | Sale(10b5-1 plan) | −12,000 | $20.11 | $241.32K | 112,622 |
| Adam Crystal President, R&D | Mar 25, 2026 | Option exercise | +12,000 | $5.20 | $62.40K | 124,622 |
| Adam Crystal President, R&D | Mar 5, 2026 | Sale(10b5-1 plan) | −20,251 | $15.00 | $303.77K | 112,622 |
| Adam Crystal President, R&D | Feb 25, 2026 | Sale(10b5-1 plan) | −54,345 | $12.77 | $693.99K | 132,873 |
| Barbara Weber Director, Executive Chair | Feb 3, 2026 | Sale | −30,186 | $12.26 | $370.08K | 1,629,587 |
| Barbara Weber Director, Executive Chair | Feb 3, 2026 | Sale | −333 | $12.90 | $4.30K | 1,629,254 |
| Daniella Beckman Chief Financial Officer | Feb 3, 2026 | Sale | −113 | $12.90 | $1.46K | 184,297 |
| Daniella Beckman Chief Financial Officer | Feb 3, 2026 | Sale | −10,204 | $12.26 | $125.10K | 184,410 |
| Adam Crystal President, R&D | Feb 3, 2026 | Sale | −18,251 | $12.26 | $223.76K | 187,419 |
| Adam Crystal President, R&D | Feb 3, 2026 | Sale | −201 | $12.90 | $2.59K | 187,218 |
| Barbara Weber Director, Executive Chair | Feb 2, 2026 | Award | +37,522 | – | – | 1,659,773 |
| Daniella Beckman Chief Financial Officer | Feb 2, 2026 | Award | +44,330 | – | – | 194,614 |
| Adam Crystal President, R&D | Feb 2, 2026 | Award | +47,460 | – | – | 205,670 |
| Malte Peters President & CEO, Director | Jan 8, 2026 | Award | +350,000 | – | – | 367,500 |
| Sung Lee Director | Jan 2, 2026 | Award | +10,000 | – | – | 10,000 |
| Trv Gp Iv, Llc 10% owner | Oct 23, 2025 | Sale | −477,401 | $10.15 | $4.85M | 13,386,574 |
| Trv Gp Iv, Llc 10% owner | Sep 25, 2025 | Sale | −500,000 | $8.02 | $4.01M | 13,863,975 |
| Trv Gp Iv, Llc 10% owner | Sep 16, 2025 | Sale | −363,541 | $7.04 | $2.56M | 14,363,975 |
| Trv Gp Iv, Llc 10% owner | Sep 8, 2025 | Sale | −86,459 | $7.04 | $608.67K | 14,727,516 |
| Trv Gp Iv, Llc 10% owner | Sep 5, 2025 | Sale | −642,906 | $7.00 | $4.50M | 14,813,975 |
| Third Rock Ventures GP IV, L.P. 10% owner | Aug 22, 2025 | Sale | −302,194 | $7.00 | $2.12M | 15,456,881 |
| Third Rock Ventures GP IV, L.P. 10% owner | Aug 19, 2025 | Sale | −1,100,000 | $7.01 | $7.71M | 15,759,075 |
| Alexis Borisy Director | Jun 5, 2025 | Award | +6,250 | – | – | 17,500 |
| Lesley Ann Calhoun Director | Jun 5, 2025 | Award | +6,250 | – | – | 12,500 |
| John B. Ketchum Director | Jun 5, 2025 | Award | +6,250 | – | – | 20,937 |
| Mace Rothenberg Director | Jun 5, 2025 | Award | +6,250 | – | – | 37,500 |
| Malte Peters Director | Jun 5, 2025 | Award | +6,250 | – | – | 17,500 |
| Adam Crystal See Remarks | Feb 5, 2025 | Sale | −6,851 | $3.16 | $21.65K | 158,210 |
| Barbara Weber Chief Executive Officer, Director | Feb 5, 2025 | Sale | −9,013 | $3.16 | $28.48K | 1,622,251 |
| Douglas Barry General Counsel | Feb 5, 2025 | Sale | −2,556 | $3.16 | $8.08K | 66,014 |
| Daniella Beckman Chief Financial Officer | Feb 5, 2025 | Sale | −3,948 | $3.16 | $12.48K | 150,284 |
| Adam Crystal See Remarks | Feb 4, 2025 | Sale | −7,432 | $2.99 | $22.22K | 165,061 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Newcomb Jessica Officer | Sep 22, 2026 | 15,231 | $340.11K | Sep 22, 2026 | Restricted Stock Units |
| Crystal Adam Officer | Aug 3, 2026 | 81,000 | $2.20M | Aug 3, 2026 | Exercise of Stock Options |
| Crossover I. SCSp Nextech Former Affiliate | Jun 17, 2026 | 3,766,081 | $113.36M | Jun 17, 2026 | Private Placement |
| Beckman Daniella Officer | Jun 11, 2026 | 1,791,726 | $51.52M | Jun 11, 2026 | Stock Option Exercise |
| Beckman Daniella Officer | Jun 10, 2026 | 4,446 | $133.38K | Jun 10, 2026 | Stock Option Exercise |
| Crystal Adam Officer | May 1, 2026 | 65,460 | $1.42M | May 1, 2026 | Exercise of Stock Options |
| Crystal Adam Officer | Mar 25, 2026 | 93,000 | $1.81M | Mar 25, 2026 | Exercise of Stock Options |
| Crystal Adam Officer | Mar 5, 2026 | 20,251 | $250.10K | Mar 5, 2026 | Exercise of Stock Options |
| Crystal Adam Officer | Feb 25, 2026 | 54,345 | $699.96K | Feb 25, 2026 | Restricted Stock Units |
| Third Rock Ventures IV, L.P. 10% Stockholder | Oct 23, 2025 | 477,401 | $3.59M | Oct 23, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 25, 2025 | 500,000 | $3.90M | Sep 25, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 17, 2025 | 363,541 | $2.67M | Sep 16, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 8, 2025 | 86,459 | $608.63K | Sep 8, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Sep 5, 2025 | 642,906 | $4.46M | Sep 5, 2025 | Pre-IPO investment |
| Third Rock Ventures IV, L.P. 10% Stockholder | Aug 22, 2025 | 302,194 | $2.09M | Aug 22, 2025 | Pre-IPO investment |